# US 11,298,323 B2 · Bioerodible drug delivery devices > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,298,323 B2 - Document ID: US11298323B2 - Status: Granted - Kind: B2 - Application number: 16/006,395 - Filed: 2018-06-12 - Published: 2018-12-13 - Granted: 2022-04-12 - Earliest claimed: 2017-06-13 - Assignees: EyePoint Pharmaceuticals, Inc. - Applicants: EyePoint Pharmaceuticals, Inc. - Inventors: Hong Guo; Jianbing Chen - Web page: https://patentgrep.com/patent/US11298323B2 ## CPC - A61K 9/0051: {Ocular inserts or implants} - A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone} - A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes} - A61K 9/204: {Polyesters, e.g. poly(lactide-co-glycolide)} - A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)} - A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)} - A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048}) - A61P 27/02: Ophthalmic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders. ## Claims ### Claim 1 An implantable bioerodible drug delivery device consisting of a bioerodible drug core consisting of a pharmaceutically active agent and polyvinyl alcohol, a bioerodible outer member that substantially surrounds the drug core, wherein the bioerodible outer member consists of poly(lactic-co-glycolic) acid (PLGA) having a lactic acid/glycolic acid present in a molar ratio ranging from and including 82:18 to 85:15; and at least one delivery port that is permeable to the pharmaceutically active agent; wherein the device is configured to be injected into the vitreous of an eye; and wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for at least one month. ### Claim 2 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the pharmaceutically active agent is selected from the group consisting of anesthetics, anti-cancer agents, anti-fungal agents, anti-viral agents, cell transport/mobility impeding agents, anti-glaucoma agents, immunological response modifiers, peptides, proteins, steroidal compounds, corticosteroids, antibacterial agents, neuro-protectants, anti-inflammatory agents, anti-allergenic agents, anti-cholinesterases, miotics, and mydriatics. ### Claim 3 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the bioerodible outer member is tubular. ### Claim 4 (depends on 3) The implantable bioerodible drug delivery device according to claim 3, wherein each end of the tubular bioerodible outer member has a delivery port. ### Claim 5 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for one month to six months. ### Claim 6 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for six months to one year. ### Claim 7 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for one year to three years. ### Claim 8 (depends on 3) The implantable bioerodible drug delivery device according to claim 3, wherein the pharmaceutically active agent is a corticosteroid. ### Claim 9 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the device is configured to provide a substantially constant dosing for at least two months. ### Claim 10 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the device is designed to fit through a needle with a gauge of 25 or larger. ### Claim 11 (depends on 4) The implantable bioerodible drug delivery device according to claim 4, wherein at least one delivery port has a polymeric cap. ### Claim 12 (depends on 4) The implantable bioerodible drug delivery device according to claim 4, wherein at least one delivery port has a polyvinyl alcohol cap. ### Claim 13 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the polyvinyl alcohol constitutes about 1 to about 20% w/w of the drug core. ### Claim 14 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the drug core was manufactured using a solution of about 5 to about 15% w/w polyvinyl alcohol. ### Claim 15 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the drug core is heat treated during manufacturing. ### Claim 16 (depends on 1) The implantable bioerodible drug delivery device according to claim 1, wherein the device is heat treated during manufacturing. ### Claim 17 An implantable bioerodible drug delivery device consisting of a bioerodible drug core consisting of a pharmaceutically active agent and polyvinyl alcohol, a coating consisting of polyvinyl alcohol, wherein the coating substantially surrounds the drug core, a bioerodible outer member that substantially surrounds the drug core and the coating, wherein the bioerodible outer member consists of poly(lactic-co-glycolic) acid (PLGA) having a lactic acid/glycolic acid molar ratio ranging from and including 82:18 to 85:15; and at least one delivery port that is permeable to the pharmaceutically active agent; wherein the device is configured to be injected into the vitreous of an eye; and wherein the device is configured to provide a substantially constant dosing rate of the pharmaceutically active agent for at least one month.